ITB300

ITB300 is a preclinical-stage therapeutic candidate being developed by ITB-Med, a Swedish biotechnology company focused on inducing immune tolerance. The asset is currently being evaluated for potential applications in organ transplantation and the treatment of immune-mediated diseases. While ITB-Med's lead program, siplizumab (ITB-101), is a monoclonal antibody targeting CD2, the specific molecular target and modality of ITB300 have not yet been publicly disclosed. The program is part of the company's broader strategy to develop therapies that reprogram the immune system to accept foreign tissue or cease attacking self-tissue, potentially reducing the reliance on chronic immunosuppressive therapy.